Opinion|Videos|August 19, 2024
Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Looking ahead, what is the most critical priority to meaningfully enhance outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency
2
New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq
3
Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs
4
Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries
5
